An experimental agent combines low-dose, extended-release formulations of two commercially available PD drugs with similar efficacy but with less daytime sleepiness and orthostatic hypotension.
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.